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Alzheimer’s disease (AD), the most common disabling
impairment in older adults, takes an unacceptable toll
on patients and families. With the growing number of
people living to older ages, it is projected to afflict more
than 100 million people around the world by 2050.
While there is an urgent need, it takes too many cogni-
tively normal (CN) individuals and too many years to
evaluate presymptomatic AD treatments using tradi-
tional clinical endpoints.
We and our colleagues have been using imaging tech-
niques to detect the brain changes associated with the
predisposition to AD in CN individuals with 2, 1 and 0
copies of the apolipoprotein E (APOE) ε4 allele, the
major late-onset AD susceptibility gene, and in CN
presenilin 1 (PSEN1) mutation carriers and non-carriers
from the world’s largest autosomal dominant early-onset
AD kindred in Antioquia, Colombia; we developed sev-
eral image-analysis techniques and a composite cogni-
tive measure with improved power; and we estimated
the sample sizes needed when using these endpoints.
We recently proposed the Alzheimer’s Prevention
Initiative (API) to help in the effort to launch an era in
AD prevention research. The API will include preclinical
AD treatment/biomarker development trials in indivi-
duals at increased genetic risk for early-onset and late-
onset AD, an extremely large Colombian early-onset
AD Prevention Registry; and an extremely large North
American Alzheimer’s Prevention Registry to support
several preclinical AD trials. The API’s first trial will test
the anti-amyloid immunization therapy crenezumab in
CN PSEN1 mutation carriers using the best established
brain imaging and cerebrospinal fluid measurements and
our composite cognitive measure as the primary clinical
endpoint. It is intended to test an anti-amyloid agent in
the preclinical treatment of AD, help determine the
extent to which a treatment’s biomarker effects predict a
clinical outcome, provide a better test of the amyloid
hypothesis, and provide raw data and biological samples
to the research community. With support from the U.S.
National Institutes of Health, philanthropic funds from
the Banner Alzheimer’s Institute, and Genentech, it is
also intended to help provide a new paradigm for
research collaboration in clinical trials.
In this presentation, we will briefly introduce the crucial
role of flourodeoxyglucose positron emission tomography
(PET), amyloid PET, structural and functional MRI in the
preclinical detection, tracking, and treatment of AD. We
will present the novel image processing methods we have
developed to help in this endeavor, as well as their imple-
mentation in the API’s preclinical treatment/biomarker
development programs.
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